|
⚲
|
| Keyboard |
| RA Capital Management LP
✚
|
|
|---|---|
| CRD # | 160174 |
| SEC # | 801-73980 |
| CIK # | 0001346824 |
| AUM | 16.40 B (2026-03-31) |
| Employees | 185 (51% Investors, 0% Brokers) |
| Fees | |
| Minimum | |
| Phone | 617-778-2500 |
| Address | 200 Berkeley Street Boston, MA 02116 |
| Source | [IAPD] [EDGAR] [Website] [Twitter] [LinkedIn] |
| Total AUM ($B) |
|---|
| Fees and Compensation — Form ADV Part 2A (3/31/2026) [Brochure] |
|---|
ITEM 5 – FEES AND COMPENSATION Within the Healthcare Funds, expenses related to private investments that are Special Investments are not necessarily allocated pro rata among all Healthcare Fund Investors, due to differing levels of participation in Special Investments. The Nexus Funds will invest in substantially the same private investments as the Healthcare Funds during the Nexus Funds’ Investment Period (as defined in the Nexus Fund offering documents) and will also bear expenses specifically related to such investments, on a pro rata basis. 95161013_3 12 WEIL\101203960\1\US.NY |
| Account Minimums and Types of Clients — Form ADV Part 2A (3/31/2026) [Brochure] |
|---|
Item 7 – Types of Clients As previously described in Item 4, RA Capital’s Advisory Clients consist of the Healthcare Funds, the Nexus Funds, the Structured Capital Funds, the Planetary Health Funds, as well as the Account. With respect to the Funds, any initial and additional subscription minimums (as applicable) are disclosed in the relevant offering documents and may be waived or modified by RA Capital or its affiliates (as the case may be). The Funds are open only to certain financially sophisticated investors who meet eligibility criteria. Generally, with respect to separately managed accounts, RA Capital determines the minimum investment amounts on a case-by-case basis. Typically, such accounts involve significant minimum investments. Certain institutions may invest in one or more Funds offered by RA Capital through their endowments or other investment mechanisms. RA Capital maintains an active diligence of the foundational science activities underway at major institutions. RA Capital may be incentivized to fund research of, license the assets of, or otherwise invest in an institution which is an investor in one or more of our Funds. The investment process is team oriented and science-based, with limited visibility into the limited partners of our Funds, minimizing the risk created by this conflict. 95161013_3 17 WEIL\101203960\1\US.NY |
| Sector | Form 13F Holdings | Value ($B) | |
|---|---|---|---|
| Ascendis Pharma A/S | 2.4 | ||
| Vaxcyte Inc | 0.7 | ||
| Rhythm Pharmaceuticals Inc | 0.6 | ||
| TYRA Biosciences Inc | 0.5 | ||
| Sionna Therapeutics Inc | 0.4 | ||
| Edgewise Therapeutics Inc | 0.3 | ||
| Newamsterdam Pharma Co NV | 0.3 | ||
| Nuvalent Inc | 0.3 | ||
| Magenta Therapeutics Inc | 0.2 | ||
| Mineralys Therapeutics Inc | 0.2 | ||
| View All | |||
| Holdings by Sector ($B) |
|---|
| Type | Form D Funds | Date | Sold | AUM |
|---|---|---|---|---|
| VC | RA Capital Nexus Fund IV LP | [2025-08-27] | 195.7 M | |
| Filed 2025-04-23 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration One year or less · Revenue Decline to Disclose | ||||
| VC | RA Capital Planetary Health Fund LP | [2023-11-29] | 122.2 M | 118.1 M |
| Filed 2025-07-22 (D/A) · Exemption 506(b), 3(c), 3(c)(1) · Remaining Indefinite · Duration More than one year · Finder's Fee $164,000 · Revenue Decline to Disclose | ||||
| VC | RA Capital Nexus III Fund LP | [2022-02-11] | 881.0 M | 971.9 M |
| Filed 2021-10-06 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration One year or less · Revenue Decline to Disclose | ||||
| VC | RA Capital Nexus II Fund LP | [2021-02-26] | 331.9 M | |
| Filed 2020-09-29 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration One year or less · Revenue Decline to Disclose | ||||
| VC | RA Capital Nexus Fund LP | [2019-07-12] | 128.9 M | 195.1 M |
| Filed 2019-07-12 (D) · Exemption 506(b), 3(c)(7) · Remaining Indefinite · Duration One year or less · Revenue Decline to Disclose | ||||
| HF | RA Capital Healthcare Fund LP | [2012-02-14] | 2,361.1 M | 14.53 B |
| Filed 2025-04-18 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $100,000 · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| AUM Breakdown | Accounts | AUM ($B) |
|---|---|---|
| By Client Type | ||
| (a) Individuals (other than high net worth individuals) | 0 | 0.0 |
| (b) Individuals (high net worth individuals) | 0 | 0.0 |
| (c) Banking or thrift institutions | 0 | 0.0 |
| (d) Investment companies | 0 | 0.0 |
| (e) Business development companies | 0 | 0.0 |
| (f) Pooled investment vehicles | 12 | 16.3 |
| (g) Pension and profit sharing plans | 0 | 0.0 |
| (h) Charitable organizations | 0 | 0.0 |
| (i) State or municipal government entities | 0 | 0.0 |
| (j) Other investment advisers | 0 | 0.0 |
| (k) Insurance companies | 0 | 0.0 |
| (l) Sovereign wealth funds and foreign official institutions | 0 | 0.0 |
| (m) Corporations or other businesses not listed above | 1 | 0.1 |
| (n) Other | 0 | 0.0 |
| Total | 13 | 16.4 |
| By Discretionary | ||
| Discretionary | 13 | 16.4 |
| Non-Discretionary | 0 | 0.0 |
| Total | 13 | 16.4 |
| By Non-United States Persons | ||
| Non-United States Persons | 5.6 | |
| United States Persons | 10.8 | |
| Total | 13 | 16.4 |
| Form D Directors | Role | # Filings | # Firms | 2011 - 2026 |
|---|---|---|---|---|
| Sophia Dilbert | Director | 109 | 44 | |
| James Keyes | Director | 153 | 31 | |
| Sabrina Foster | Director | 43 | 16 | |
| Sherri Fleming | Director | 53 | 12 | |
| Derek Candy | Director | 28 | 8 | |
| Victor Valencia | Director | 14 | 6 | |
| Sinead Wagner | Director | 8 | 3 | |
| Peter Kolchinsky | Director, Executive Officer, Promoter | 42 | 2 | |
| Rajeev Shah | Director, Executive Officer, Promoter | 30 | 2 | |
| Kyle Teamey | Executive Officer | 11 | 2 | |
| View All | ||||
| EDGAR Form | CIK | 2011 - 2026 |
|---|---|---|
| 13F-HR | [0001346824] | |
| 3 | [0001346824] | |
| 4 | [0001346824] | |
| SC 13D | [0001346824] | |
| SC 13G | [0001346824] |
| Firm Profile (Form ADV) | |
|---|---|
| Discretionary AUM | $1.5B |
| Serves | Institutional |
| Fund Types | Hedge Fund |
| LEI | 549300ZV6X2KFAD7UG21 |
| Insider Transaction (Form 3/4/5) | Date | Action | Shares | Price | Value ($) |
|---|---|---|---|---|---|
|
Wave Life Sciences Pte Ltd WVE
Ordinary Shares
|
2026-03-30 | Buy | 971,091 | $6.50 | 6,312,092 |
|
Mineralys Therapeutics Inc MLYS
Common Stock
|
2026-03-30 | Buy | 58,300 | $24.16 | 1,408,528 |
|
Mineralys Therapeutics Inc MLYS
Common Stock
|
2026-03-27 | Buy | 310,700 | $23.67 | 7,354,269 |
|
Wave Life Sciences Pte Ltd WVE
Ordinary Shares
|
2026-03-27 | Buy | 2,495,623 | $6.43 | 16,046,856 |
|
Wave Life Sciences Pte Ltd WVE
Ordinary Shares
|
2026-03-26 | Buy | 4,954,558 | $6.06 | 30,024,621 |
|
Wave Life Sciences Pte Ltd WVE
Ordinary Shares
|
2026-03-26 | Buy | 351,224 | $6.38 | 2,240,809 |
|
Acumen Pharmaceuticals Inc ABOS
Common Stock
|
2026-03-16 | Grant | 6,060,606 | $3.30 | 20,000,000 |
|
Bicara Therapeutics Inc BCAX
Common Stock
|
2026-02-26 | Buy | 300,000 | $16.00 | 4,800,000 |
|
Bicara Therapeutics Inc BCAX
Pre-Funded Warrant (Right to Buy) · derivative
|
2026-02-26 | Buy | 2,200,000 | $16.00 | 35,200,000 |
|
Mineralys Therapeutics Inc MLYS
Common Stock
|
2026-02-19 | Grant | 6,200 | $0.00 | |
|
Mineralys Therapeutics Inc MLYS
Stock Option (Right to Buy) · derivative
|
2026-02-19 | Grant | 8,300 | $0.00 | |
|
Evommune Inc EVMN
Common Stock
|
2026-02-17 | Grant | 35,868 | $27.88 | 1,000,000 |
|
SpyGlass Pharma Inc SGP
Series C-2 Preferred Stock · derivative
|
2026-02-09 | Conversion | 767,294 | ||
|
SpyGlass Pharma Inc SGP
Common Stock
|
2026-02-09 | Buy | 3,441,966 | $16.00 | 55,071,456 |
|
SpyGlass Pharma Inc SGP
Series C-2 Preferred Stock · derivative
|
2026-02-09 | Conversion | 1,150,941 | ||
|
SpyGlass Pharma Inc SGP
Common Stock
|
2026-02-09 | Buy | 248,034 | $16.00 | 3,968,544 |
|
SpyGlass Pharma Inc SGP
Common Stock
|
2026-02-09 | Conversion | 1,806,644 | ||
|
SpyGlass Pharma Inc SGP
Series D Preferred Stock · derivative
|
2026-02-09 | Conversion | 222,591 | ||
|
SpyGlass Pharma Inc SGP
Series D Preferred Stock · derivative
|
2026-02-09 | Conversion | 272,056 | ||
|
SpyGlass Pharma Inc SGP
Common Stock
|
2026-02-09 | Conversion | 2,524,473 | ||
| showing 20 of 200 most recent transactions | |||||
| Comparable Firms | State | AUM |
|---|---|---|
|
RWC Asset Management LLP
✚
|
17.32 B | |
|
Monarch Alternative Capital LP
✚
|
NY | 16.69 B |
|
Compass Rose Asset Management LP
✚
|
NY | 16.50 B |
|
Freestone Grove Partners LP
✚
|
CA | 16.48 B |
|
O'Connor Alternative Investments LLC
✚
|
NY | 16.37 B |
|
Varde Management LP
✚
|
NY | 16.13 B |
|
Whitebox Advisors LLC
✚
|
MN | 15.74 B |
|
Soroban Capital Partners LP
✚
|
NY | 15.67 B |
|
Weiss Asset Management LP
✚
|
MA | 15.56 B |
|
Intech Investment Management LLC
✚
|
FL | 15.47 B |